Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74445 | 0.94 | L3MBTL1 (0.50) | L3MBTL1HSD17B10POLBTLR4ALDH1A1 | |
| SCHEMBL3193620 | 0.85 | L3MBTL1 (0.42) | L3MBTL1HSD17B10POLBTLR4ALDH1A1 | |
| SCHEMBL8826699 | 0.85 | FKBP5 (0.43) | L3MBTL1HSD17B10POLBTLR4ALDH1A1 | |
| SCHEMBL907623 | 0.84 | MAPT (0.45) | HSD17B10POLBTLR4ALDH1A1PPM1B | |
| SCHEMBL27405623 | 0.84 | MAPT (0.45) | HSD17B10POLBTLR4ALDH1A1PPM1B | |
| SCHEMBL55591 | 0.82 | L3MBTL1 (0.61) | L3MBTL1HSD17B10POLBALDH1A1HTT | |
| SCHEMBL14812115 | 0.82 | L3MBTL1 (0.61) | L3MBTL1HSD17B10POLBALDH1A1HTT | |
| SCHEMBL14811830 | 0.82 | L3MBTL1 (0.61) | L3MBTL1HSD17B10POLBALDH1A1HTT | |
| SCHEMBL20553752 | 0.82 | HSD17B10 (0.57) | L3MBTL1HSD17B10POLBALDH1A1PPM1B | |
| SCHEMBL24878938 | 0.78 | L3MBTL1 (0.42) | L3MBTL1HSD17B10POLBTLR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| EP-2268612-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | MMP11, MMP10, MMP9 | L3MBTL1 4722/4885HSD17B10 308/4885POLB 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.